J cachexia sarcopenia muscle - 2022 - Wilkinson - Associations between frailty trajectories and cardiovascular renal and.pdf (616.07 kB)
Download file

Associations between frailty trajectories and cardiovascular, renal, and mortality outcomes in chronic kidney disease

Download (616.07 kB)
journal contribution
posted on 05.08.2022, 09:47 authored by Thomas J Wilkinson, Joanne Miksza, Francesco Zaccardi, Claire Lawson, Andrew C Nixon, Hannah ML Young, Kamlesh Khunti, Alice C Smith

Background

Frailty is characterized by the loss of biological reserves and vulnerability to adverse outcomes. In individuals with chronic kidney disease (CKD), numerous pathophysiological factors may be responsible for frailty development including inflammation, physical inactivity, reduced energy intake, and metabolic acidosis. Given that both CKD and frailty incur a significant healthcare burden, it is important to understand the relationship of CKD and frailty in real-world routine clinical practice, and how simple frailty assessment methods (e.g. frailty indexes) may be useful. We investigated the risk of frailty development in CKD and the impact of frailty status on mortality and end-stage kidney disease (ESKD).


Methods

A retrospective cohort study using primary care records from the Clinical Practice Research Datalink linked to Hospital Episode Statistics and the UK Office for National Statistics was undertaken in 819 893 participants aged ≥40 years, of which 140 674 had CKD. Frailty was defined using an electronic frailty index, generated electronically from primary care records. Cox proportional hazard and flexible parametric survival models were used to investigate the risk of developing frailty and the effect of frailty on risk of all-cause and cardiovascular mortality, and ESKD.


Results

The mean age of those with CKD was 77.5 (SD 9.7) years [61.0 (SD 12.1) years in no-CKD group]; 62.0% of the CKD group were female (compared with 53.3% in no-CKD group). The mean estimated glomerular filtration rate of those with CKD was 46.1 (SD 9.9) mL/min/1.73 m2. The majority of those with CKD (75.3%) were frail [vs. 45.4% in those without CKD (no-CKD)]. Over 3 years (median), 69.5% of those with CKD developed frailty. Compared with no-CKD, those with CKD had increased rates of developing mild (hazard ratio: 1.02; 95% confidence interval: 1.01–1.04), moderate (1.30; 1.26–1.34), and severe (1.50; 1.37–1.65) frailty. Mild (1.22; 1.19–1.24), moderate (1.60; 1.56–1.63), and severe (2.16; 2.11–2.22) frailty was associated with increased rates of all-cause and cardiovascular-related mortality (mild 1.35; 1.31–1.39; moderate 1.96; 1.90–2.02; and severe 2.91; 2.81–3.02). All stages of frailty significantly increased ESKD rates.


Conclusions

Frailty is highly prevalent and associated with adverse outcomes in people with CKD, including mortality and risk of ESKD. Preventative interventions should be initiated to mitigate the development of frailty. The use of a simple frailty index, generated electronically from health records, can predict outcomes and may aid prioritization for management of people with frailty.

Funding

NIHR Development and Skills Enhancement Award

Leicester Real World Evidence Unit, University of Leicester

NIHR Leicester Biomedical Research Centre

NIHR Applied Research Collaboration East Midlands

Stoneygate Trust

History

Author affiliation

Leicester Kidney Lifestyle Team, Department of Health Sciences, University of Leicester

Version

VoR (Version of Record)

Published in

Journal of Cachexia, Sarcopenia and Muscle

Publisher

WILEY

issn

2190-5991

eissn

2190-6009

Acceptance date

25/06/2022

Copyright date

2022

Available date

05/08/2022

Spatial coverage

Germany

Language

English